Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Therapy Trends KOL Insight: Rheumatoid Arthritis [2019]

Product Code:
596201293
Publication Date:
March 2019
Format:
PDF + PPTX
Price:
$8,920

How are Xeljanz and Olumiant impacting the RA treatment landscape?

Now that Pfizer’s Xeljanz and Eli Lilly/Incyte’s Olumiant are both available in the US and EU, KOLs weigh in on how these JAK inhibitors are faring and which of the two is coming out on top and why. KOLs also give their opinions on Sanofi/Regeneron’s Kevzara and how this new IL-6 inhibitor is performing against Roche’s well-established Actemra/RoActemra. Additionally, the experts discuss how AbbVie’s upadacitinib and Galapagos/Gilead Sciences’ filgotinib shape up in an ever competitive JAK inhibitor market, as well as how Can-Fite’s piclidenoson (CF 101) could disrupt the treatment paradigm. Experts also give their views on biosimilar anti-TNF uptake and factors contributing to their success/failure in respective markets.Twelve US and European KOLs offer their candid insights on these issues and more.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • Many more biosimilar anti-TNFs are being approved. But how are KOLs using these products and what factors are driving/limiting their usage?
  • How well is Xeljanz faring in Europe? Can Pfizer’s Xeljanz be as successful in the European market as it has been in the US? Why?/Why not?
  • Has Olumiant been a success in the US? What factors are contributing to Olumiant’s current prescribing trend and what advice do KOLs offer?
  • Roche’s Actemra/RoActemra now has a rival IL-6 inhibitor, Kevzara. How has Kevzara fared since its launch and what strategies could Roche employ to retain market share?
  • Can upadacitinib provide specific advantages over current JAK inhibitors? What do experts think of this new JAK inhibitor?
  • Will filgotinib be a threat to current JAK inhibitors? What do KOLs think of filgotinib’s safety profile so far?
  • Can-Fite’s piclidenoson is in late-stage development for RA. According to KOLs, what will this agent need to show in order to succeed against methotrexate?
  • KOLs discuss important developments that could shape the future treatment of RA. How do KOLs view earlier-stage approaches and what do they think of general trends such as dose-tapering?
Request sample pages

Back to the top

Quotes

“We need to treat as early as possible, and not wait for progression. We need to identify patients early, and treat them aggressively; that is very important.”
European Opinion Leader

“Upadacitinib has already been shown to be superior to adalimumab and I assume that we will see the same with filgotinib. I will not be surprised if that will be the case, but the big question is whether that difference is clinically important. That is the big question.”
European Key Opinion Leader

Sample of therapies covered

Marketed Therapies

1. Anti-TNFs

  • Humira (adalimumab; AbbVie)
  • Enbrel (etanercept; Amgen/Pfizer)
  • Remicade (infliximab; Janssen Biotech/Merck & Co.)
  • Cimzia (certolizumab pegol; UCB)
  • Simponi (golimumab; Janssen Biotech/Merck & Co.)

2. Biosimilar anti-TNFs: companies involved in biosimilar anti-TNFs: Sandoz; Amgen; Samsung Bioepis/Biogen; Celltrion/Pfizer; Boehringer Ingelheim

3. Actemra/RoActemra (tocilizumab; Roche)

4. Kevzara (sarilumab; Sanofi/Regeneron)

5. Orencia (abatacept; Bristol-Myers Squibb)

6. Rituxan/MabThera (rituximab; Roche/Biogen)

7. Xeljanz (tofacitinib; Pfizer)

8. Olumiant (baricitinib; Incyte/Eli Lilly)

 

Pipeline Therapies

9. Orencia (abatacept; Bristol-Myers Squibb)

10. Rituxan/MabThera (rituximab; Roche/Biogen)

11. Xeljanz (tofacitinib; Pfizer)

12. Olumiant (baricitinib; Incyte/Eli Lilly)

KOLs interviewed

KOLs from North America

  • Prof Michael E Weinblatt, MD, is Professor of Medicine at Harvard Medical School. Dr. Weinblatt serves as Co-director of Clinical Rheumatology at the Brigham and Women's Hospital
  • Dr Petros Efthimiou, MD, is Associate Chief of Rheumatology at New York Methodist Hospital, and an Associate Professor of Medicine and Rheumatology at Weill Cornell Medical College
  • Prof Fleischmann, MD, is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas, and co-Medical Director of the Metroplex Clinical Research Center in Dallas, TX
  • Prof. Stanley B Cohen, MD, is Clinical Associate Professor in the Department of Internal Medicine at Southwestern Medical School in Dallas and director of both the arthritis division of the Health South Rehabilitation Center in Texas, and the Osteoporosis Center at the Irving Healthcare System
  • Dr Rohit Aggarwal MD, is Associate Professor of Medicine and Medical Director, Arthritis and Autoimmunity Center, Division of Rheumatology, Department of Medicine at the University of Pittsburgh, Pittsburgh, PA, USA
  • Dr Roberto Caricchio, MD, is Interim Section Chief, Rheumatology; Associate Professor, Medicine; Associate Professor, Microbiology and Immunology; and Director at Temple Lupus Clinic, Temple University, Philadelphia, PA, USA

KOLs from Europe

  • Prof Paul Emery, is the Arthritis Research UK Professor of Rheumatology and Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine. He is also the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, UK
  • Prof Tore K Kvien, is Professor of Rheumatology at the University of Oslo and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo, Norway
  • Prof Ronald F van Vollenhoven, is Professor and Director of the Amsterdam Rheumatology and Immunology Center ARC; Chief of the Department of Rheumatology and Clinical Immunology at the AMC; and Head of the Department of Rheumatology at VUMC (VU University Medical Center) in Amsterdam, the Netherlands
  • Prof Ferdinand Breedveld, is Professor and Head of the Department of Internal Medicine and Rheumatology at Leiden University Medical Centre, Leiden, the Netherlands
  • Anonymous, German KOL, is a Professor of Medicine at a leading German university hospital
  • Anonymous, German KOL, is a Professor of Medicine at a leading German university hospital

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved